Press coverage about Bioblast Pharma (NASDAQ:ORPN) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bioblast Pharma earned a news impact score of 0.11 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.3388071527594 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Bioblast Pharma (ORPN) remained flat at $$2.59 during trading on Friday. 15,769 shares of the company were exchanged, compared to its average volume of 89,844. The firm has a market capitalization of $8.79, a P/E ratio of -1.01 and a beta of -0.05. Bioblast Pharma has a 1 year low of $1.49 and a 1 year high of $7.75.
Separately, ValuEngine raised Bioblast Pharma from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th.
About Bioblast Pharma
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.